- Conditions
- Chronic Kidney Diseases, Pediatric Kidney Disease
- Interventions
- Empagliflozin 10 MG
- Drug
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 12 Years to 25 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 214
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Bladder, Neurogenic
- Interventions
- tamsulosin hydrochloride, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 2 Years to 16 Years
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Tampa, Florida • St Louis, Missouri + 4 more
- Conditions
- Acute Kidney Injury, Fluid Overload
- Interventions
- Continuous Renal Replacement Therapy
- Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 1 Year to 25 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Chronic Kidney Disease, Pediatric Urology
- Interventions
- NSAIDs, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Months to 25 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Overactive Detrusor, Neurogenic Bladder
- Interventions
- Oxybutynin, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 3 Years to 16 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 10
- States / cities
- Loma Linda, California • Orange, California • Aurora, Colorado + 7 more
- Conditions
- Wolfram Syndrome, Diabetes Mellitus, Optic Nerve Atrophy, Ataxia
- Interventions
- dantrolene sodium
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 5 Years to 60 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Lupus Nephritis
- Interventions
- Mycophenolate Mofetil
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 8 Years to 20 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 19
- States / cities
- San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 14 more
- Conditions
- Sarcoma, Neuroblastoma, Wilms Tumor, Osteosarcoma, Brain Tumor
- Interventions
- Pazopanib (GW786034)
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 25 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
- Interventions
- Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 115
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 93 more
- Conditions
- Pediatric Solid Tumor, Sarcoma, Neuroblastoma, Wilms Tumor
- Interventions
- Not listed
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 5
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 1 more
- Conditions
- Congenital Heart Disease, Cardiopulmonary Bypass, Myocardial Injury, Acute Kidney Injury, Acute Lung Injury
- Interventions
- RIPC, Control
- Procedure
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Bronchiolitis
- Interventions
- Not listed
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 37 Weeks to 2 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- LIPOSORBER® LA-15
- Device
- Lead sponsor
- Kaneka Medical America LLC
- Industry
- Eligibility
- Up to 75 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 10
- States / cities
- Loma Linda, California • Wilmington, Delaware • Grand Rapids, Michigan + 5 more
- Conditions
- Spinal Cord Injuries, Neurogenic Bladder
- Interventions
- Locomotor Training
- Procedure
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Acute Urinary Tract Infection, Urinary Tract Infection
- Interventions
- Placebo, Dexamethasone
- Drug
- Lead sponsor
- Nader Shaikh
- Other
- Eligibility
- 2 Months to 6 Years
- Enrollment
- 546 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Columbus, Ohio • Pittsburgh, Pennsylvania + 3 more
- Conditions
- Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor, Melanoma, Hepatoblastoma, Hepatocellular Carcinoma, Neuroblastoma, Wilms Tumor
- Interventions
- Cryoablation Therapy, Nivolumab, Ipilimumab
- Procedure · Drug
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 1 Year to 39 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
- Interventions
- Paricalcitol
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 0 Years to 9 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 14
- States / cities
- Little Rock, Arkansas • Redwood City, California • Washington D.C., District of Columbia + 10 more
- Conditions
- Recurrent Urinary Tract Infection
- Interventions
- Lactobacillus reuteri DSM 17938, trimethoprim/sulfamethoxazole
- Dietary Supplement · Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 3 Months to 17 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Carcinoid, Neuroendocrine
- Interventions
- Seneca Valley Virus (biological agent)
- Drug
- Lead sponsor
- Neotropix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 10
- States / cities
- Ocoee, Florida • Indianapolis, Indiana • Baltimore, Maryland + 7 more
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Wilm's Tumor, Ewing's Sarcoma
- Interventions
- Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
- Drug
- Lead sponsor
- Jennerex Biotherapeutics
- Industry
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Houston, Texas
- Conditions
- AKI - Acute Kidney Injury, Arrythmia, Congenital Heart Disease
- Interventions
- total magnesium, ionized magnesium
- Diagnostic Test · Device
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 0 Years to 18 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Malignant Glioma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
- Interventions
- Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Samotolisib, X-Ray Imaging
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 125
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 96 more
- Conditions
- Soft Tissue Sarcoma, Lymphoma, Leukemia, Wilms' Tumor, Osteosarcoma
- Interventions
- Liposomal Vincristine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Retinoblastoma, Clear Cell Sarcoma, Renal Cell Carcinoma, Rhabdoid Tumor, Wilms Tumor, Hepatoblastoma, Neuroblastoma, Germ Cell Tumors, Ewings Sarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Osteosarcoma, Rhabdomyosarcoma
- Interventions
- Simvastatin, Cyclophosphamide, Topotecan, Myeloid growth factor
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 1 Year to 29 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia